1. Scrip
  2. >>Leadership

Teva Hopes For Revenue Growth For First Time Since 2017

 
• By Jessica Merrill

The company’s new CEO Richard Francis is aiming for revenue growth this year; it would be the first time since 2017.

turn around
Teva hopes to reverse years of revenue declines • Source: Shutterstock

Teva Pharmaceutical Industries Ltd. hasn’t delivered annual revenue growth since 2017, but the company is hoping that 2023 may be the year it finally begins to reverse years of revenue declines. Teva, led by new CEO Richard Francis, updated investors on the 2023 financial outlook during the company’s fourth quarter update on 8 February.

Management guided investors to anticipate flat-to-moderate revenue growth in 2023, with revenues reaching $14.8bn-$15.4bn, which would be growth of up...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

PureTech Ponders Way Forward As CEO Exits

 
• By Kevin Grogan

Bharatt Chowrira departs days after firm’s chair stepped down.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

More from Scrip

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By Mandy Jackson

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 
• By Alaric DeArment

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 
• By Joseph Haas, Manas Mishra, and Sushmita Panda

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.